FDA Accelerates Psychedelic Drug Review with Priority Review Vouchers for Compass, Usona and Transcend in Mental Health Push

The U.S. Food and Drug Administration has granted priority review vouchers to three companies developing psychedelic-based medicines for mental health conditions, accelerating the regulatory pathway for potential new treatments.

The vouchers were awarded to Compass Pathways for its synthetic psilocybin formulation targeting treatment-resistant depression, to the Usona Institute for its psilocybin-based medicine for major depressive disorder and to Transcend Therapeutics for its MDMA-like compound, methylone, intended for post-traumatic stress disorder.

This action falls under the FDA Commissioner’s National Priority Voucher pilot program, launched the previous year to fast-track review for certain drugs and biological products seeking approval, potentially reducing the time required for these treatments to reach patients.